Literature DB >> 22945450

Progression-free survival versus overall survival in ovarian cancer: where are we now?

Susana Banerjee1, Stan Kaye.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22945450     DOI： 10.1007/s11912-012-0263-7

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


× No keyword cloud information.
  9 in total

1.  Progression-free survival: meaningful or simply measurable?

Authors:  Christopher M Booth; Elizabeth A Eisenhauer
Journal:  J Clin Oncol       Date:  2012-02-27       Impact factor: 44.544

Review 2.  Review of oncology and hematology drug product approvals at the US Food and Drug Administration between July 2005 and December 2007.

Authors:  Rajeshwari Sridhara; John R Johnson; Robert Justice; Patricia Keegan; Aloka Chakravarty; Richard Pazdur
Journal:  J Natl Cancer Inst       Date:  2010-01-29       Impact factor: 13.506

3.  Detecting an overall survival benefit that is derived from progression-free survival.

Authors:  Kristine R Broglio; Donald A Berry
Journal:  J Natl Cancer Inst       Date:  2009-11-09       Impact factor: 13.506

Review 4.  2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference.

Authors:  Gavin C E Stuart; Henry Kitchener; Monica Bacon; Andreas duBois; Michael Friedlander; Jonathan Ledermann; Christian Marth; Tate Thigpen; Edward Trimble
Journal:  Int J Gynecol Cancer       Date:  2011-05       Impact factor: 3.437

5.  A phase 3 trial of bevacizumab in ovarian cancer.

Authors:  Timothy J Perren; Ann Marie Swart; Jacobus Pfisterer; Jonathan A Ledermann; Eric Pujade-Lauraine; Gunnar Kristensen; Mark S Carey; Philip Beale; Andrés Cervantes; Christian Kurzeder; Andreas du Bois; Jalid Sehouli; Rainer Kimmig; Anne Stähle; Fiona Collinson; Sharadah Essapen; Charlie Gourley; Alain Lortholary; Frédéric Selle; Mansoor R Mirza; Arto Leminen; Marie Plante; Dan Stark; Wendi Qian; Mahesh K B Parmar; Amit M Oza
Journal:  N Engl J Med       Date:  2011-12-29       Impact factor: 91.245

6.  Incorporation of bevacizumab in the primary treatment of ovarian cancer.

Authors:  Robert A Burger; Mark F Brady; Michael A Bookman; Gini F Fleming; Bradley J Monk; Helen Huang; Robert S Mannel; Howard D Homesley; Jeffrey Fowler; Benjamin E Greer; Matthew Boente; Michael J Birrer; Sharon X Liang
Journal:  N Engl J Med       Date:  2011-12-29       Impact factor: 91.245

7.  OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.

Authors:  Carol Aghajanian; Stephanie V Blank; Barbara A Goff; Patricia L Judson; Michael G Teneriello; Amreen Husain; Mika A Sovak; Jing Yi; Lawrence R Nycum
Journal:  J Clin Oncol       Date:  2012-04-23       Impact factor: 44.544

8.  Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer.

Authors:  Jonathan Ledermann; Philipp Harter; Charlie Gourley; Michael Friedlander; Ignace Vergote; Gordon Rustin; Clare Scott; Werner Meier; Ronnie Shapira-Frommer; Tamar Safra; Daniela Matei; Euan Macpherson; Claire Watkins; James Carmichael; Ursula Matulonis
Journal:  N Engl J Med       Date:  2012-03-27       Impact factor: 91.245

9.  Resistance to therapy caused by intragenic deletion in BRCA2.

Authors:  Stacey L Edwards; Rachel Brough; Christopher J Lord; Rachael Natrajan; Radost Vatcheva; Douglas A Levine; Jeff Boyd; Jorge S Reis-Filho; Alan Ashworth
Journal:  Nature       Date:  2008-02-10       Impact factor: 49.962
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.